Acquisition Completed
Esperion Therapeutics acquisition of Corstasis Therapeutics
US$75m consideration
Announced 3 Mar 2026
Advisers
- Target
- Corstasis Therapeutics
- Acquirer
- Esperion Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 2 Apr 2026
- Sector
- Pharma
- Tags
- Pharma, Cardiovascular
In the league tables
- M&A financial advisers, 2026 to date Jefferies #14 · PJT Partners #16
- M&A financial advisers, completed, 2026 to date Jefferies #22 · PJT Partners #27
- M&A legal advisers, 2026 to date Gibson Dunn #16 · Arnold & Porter #36
- M&A legal advisers, completed, 2026 to date Gibson Dunn #11 · Arnold & Porter #64
Similar deals
- ARCHIMED acquisition of Esperion Therapeutics May 2026 · US$1.1bn · Pharma
- Tarsus Pharmaceuticals acquisition of iRenix Medical Jul 2026 · US$75m · Ophthalmology
- Shionogi & Co. acquisition of Shionogi-Apnimed Sleep Science Apr 2026 · US$100m · Pharma
- Nuvo Pharmaceuticals (Ireland) DAC acquisition of Cumberland FDA-approved commercial products and related assets Apr 2026 · US$100m · Pharma
- AnaptysBio outstanding common stock share buy-back Mar 2026 · US$100m · Biotech
Sources
- 3 Mar 2026 Press release (EX-99.1, exhibit), Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ sec.gov
- 2 Apr 2026 Press release (EX-99.1, exhibit), Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) sec.gov


